Skip to main content
. 2022 Sep 19;23(18):10946. doi: 10.3390/ijms231810946

Figure 1.

Figure 1

GFAP is increased in CSF after aHSCT while other MS biomarkers appear unchanged. Biomarker levels in the CSF pre- and 24 months post-aHSCT in MS patients. Concentrations in pg/mL of NfL, GFAP, CXCL9, CXCL10 and CXCL13 and in ng/ml of CHI3L1 are shown. Detection limits are visualized with a dotted line, number of patients are indicated below each boxplot. Wilcoxon test was used to detect significance, **** for p ≤ 0.0001.